Search

Corvus Pharmaceuticals Inc

Geschlossen

10.01 7.63

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

9.19

Max

9.48

Schlüsselkennzahlen

By Trading Economics

Einkommen

-4.3M

-18M

EPS

-0.19

Angestellte

37

EBITDA

-5.3M

-17M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+213.5% upside

Dividenden

By Acuity

Nächstes Ergebnis

3. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-286M

839M

Vorheriger Eröffnungskurs

2.38

Vorheriger Schlusskurs

10.01

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Okt. 2026, 23:56 UTC

Globe Life Inc. is seeing notable strength in after-market trading, rising from a low shortly after the market closed to a peak later in the session.

14. Okt. 2026, 23:56 UTC

Assurant Inc is trading modestly higher in after-market hours, marking its fourth consecutive session of gains and positioning above its 20-day moving average.

14. Okt. 2026, 23:56 UTC

Correlated Moves

Citizens Financial Group Inc is modestly higher in after-market trading, following Fifth Third Bancorp's advance and a recent trend of higher daily closes.

14. Okt. 2026, 23:56 UTC

Correlated Moves

Everest Group Ltd rose in after-market trading, achieving its highest level of the session, following four consecutive days of gains and moving in sympathy with Chubb Limited.

14. Okt. 2026, 23:56 UTC

Social Media
News

Cboe Global Markets receives SEC approval to list options tied to key performance indicators, enhancing its prediction markets offerings in collaboration with Robinhood Markets.

14. Okt. 2026, 23:56 UTC

Martin Marietta Materials Inc has advanced modestly in after-market trading, recovering from earlier declines to finish near the peak of its range.

14. Okt. 2026, 23:56 UTC

Curtiss-Wright Corp shares are trading lower in after-market hours, retracing from an earlier gain and remaining below their 20-day moving average.

14. Okt. 2026, 23:56 UTC

Correlated Moves

Allstate Corp shares advanced modestly in after-market trading, reaching their highest cumulative return since Wednesday's close, amid a rise in Chubb Limited shares.

14. Okt. 2026, 23:56 UTC

News

Parker-Hannifin will webcast its Annual Meeting of Shareholders on October 28, 2026, continuing its strong track record of 70 consecutive years of dividend increases.

14. Okt. 2026, 23:56 UTC

Iron Mountain Inc is trading roughly flat in after-market hours, continuing a small decline since Wednesday's close and below its 20-day moving average.

14. Okt. 2026, 23:56 UTC

VeriSign, Inc. is trading modestly higher in after-market hours, with a cumulative return of 0.62% since Wednesday's close, remaining above its 20-day moving average.

14. Okt. 2026, 23:56 UTC

Correlated Moves

Strategy Inc shares declined in after-market trading, continuing a downward trend amid falling Bitcoin prices and remaining significantly below their 20-day moving average.

14. Okt. 2026, 23:56 UTC

Ralph Lauren Corp shares advanced modestly in after-market trading, maintaining an upward trajectory since Wednesday's close and remaining significantly above its 20-day moving average.

14. Okt. 2026, 23:56 UTC

Correlated Moves

Salesforce Inc shares are trading modestly lower in after-market hours.

14. Okt. 2026, 23:56 UTC

Correlated Moves

S&P Global Inc is trading higher in after-market hours, maintaining a position just above its previous close, while Moody's Corp shows a slight gain.

14. Okt. 2026, 23:52 UTC

News

A securities class action lawsuit has been filed against AppLovin Corporation, alleging false statements about its generative AI video feature and development delays.

14. Okt. 2026, 23:52 UTC

Campbell's Co shares advanced in after-market trading, showing unusual upward movement from a low point shortly after the market closed.

14. Okt. 2026, 23:52 UTC

Australia's September Employment Change data set for October 15, with a forecasted increase of 20,000 jobs amid cautious optimism about potential RBA interest rate hikes.

14. Okt. 2026, 23:52 UTC

Australia's September Employment Change Data Set to Show Modest Job Growth Amid Mixed Economic Signals and Potential Interest Rate Hikes.

14. Okt. 2026, 23:52 UTC

Australia's September unemployment rate release on October 15 is expected to remain steady at 4.6%, with potential implications for interest rates amid inflation concerns and fluctuating business sentiment.

14. Okt. 2026, 23:52 UTC

Japan's Machinery Orders MoM data set for October 14, with a modest forecasted increase of 0.03% following July’s decline.

14. Okt. 2026, 23:52 UTC

U.S. Business Inventories Expected to Rise 0.4% Amid Inflation Concerns and Market Volatility Ahead of Fed Decisions

14. Okt. 2026, 23:52 UTC

Brazil's BCB Focus Market Readout on October 19, 2026, expected to address rising global interest rates and inflation concerns impacting monetary policy decisions.

14. Okt. 2026, 23:52 UTC

Halozyme Therapeutics Inc is trading higher in after-market hours, continuing an upward trend since Wednesday's close and remaining above its 20-day moving average.

14. Okt. 2026, 23:52 UTC

News

Enphase Energy Inc shares are declining in after-market hours amid a broader market downturn, particularly in semiconductor stocks, despite recent product shipments in India.

14. Okt. 2026, 23:52 UTC

Correlated Moves

Silicon Motion Technology Corp shares declined in after-market hours, reflecting broader semiconductor losses amid rising inflationary pressures and a drop in the Nasdaq.

14. Okt. 2026, 23:51 UTC

Visa Inc's shares advanced modestly in after-market trading, supported by a significant rise in the Transaction & Payment Processing Services sub-sector.

14. Okt. 2026, 23:51 UTC

Correlated Moves

Alliant Energy Corp is trading modestly higher in after-market hours, above its 20-day moving average, alongside a slight increase in NextEra Energy Inc.

14. Okt. 2026, 23:51 UTC

Allegion PLC shares advanced modestly in after-market trading, continuing a steady rise since Wednesday's close and reaching a high point near the upper end of its one-month range.

14. Okt. 2026, 23:51 UTC

McCormick & Company Inc shares advanced modestly in after-market trading, reaching their highest cumulative return since Wednesday's close amid unusual activity.

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

213.5% Vorteil

12-Monats-Prognose

Durchschnitt 29.5 USD  213.5%

Hoch 33 USD

Tief 27 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

4

Buy

0

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat